Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TK2 | O00142 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128956 | 1.00 | TK1 (0.48) | TK1LMNATSHRALBPKM | |
| SCHEMBL27636538 | 0.81 | LMNA (0.38) | TK1LMNATSHRALBPKM | |
| SCHEMBL9449648 | 0.81 | LMNA (0.38) | TK1LMNATSHRALBPKM | |
| SCHEMBL27532981 | 0.81 | LMNA (0.38) | TK1LMNATSHRALBPKM | |
| Phosphoric Acid SCHEMBL16012924 | 0.81 | TK1 (0.46) | TK1LMNATSHRALBPKM | |
| SCHEMBL3813740 | 0.81 | LMNA (0.41) | TK1LMNATSHRALBPKM | |
| SCHEMBL7745421 | 0.80 | TK1 (0.50) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL6258929 | 0.80 | TK1 (0.50) | TK1LMNATSHRBLMPMP22 | |
| 3-Methylthymidine SCHEMBL17794002 | 0.80 | TK1 (0.50) | TK1LMNATSHRBLMPMP22 | |
| 3-Methylthymidine SCHEMBL2246880 | 0.80 | TK1 (0.50) | TK1LMNATSHRBLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104812383-A | Combination of therapeutic agents for treating HCV infection | HOFFMANN LA ROCHE | 2015-07-29 | — | — | CN | claimed |
| CN-102020697-B | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication | F. HOFFMANN-LA ROCHE LTD. (CH) | 2014-10-29 | — | — | CN | claimed |
| CN-102712644-A | Novel macrocyclic inhibitors of hepatitis C virus replication | HOFFMANN LA ROCHE | 2012-10-03 | — | — | CN | claimed |
| CN-1889970-B | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication | INTERMUNE INC | 2012-06-13 | — | — | CN | claimed |
| CN-102361641-A | Combination of a nucleoside polymerase inhibitor with a macrocyclic protease inhibitor and use thereof in the treatment of hepatitis C, liver fibrosis and impaired liver function | INTERMUNE INC | 2012-02-22 | — | — | CN | claimed |
| CN-102020697-A | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication | INTERMUNE INC | 2011-04-20 | — | — | CN | claimed |
| EP-2282762-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2011-02-16 | — | — | EP | claimed |
| WO-2009142842-A9 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | claimed |
| JP-4584260-B2 | — | — | 2010-11-17 | — | — | JP | claimed |
| WO-2009142842-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| CN-1938311-A | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE INC (US) | 2007-03-28 | — | — | CN | claimed |
| CN-1889970-A | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication | INTERMUNE INC (US) | 2007-01-03 | — | — | CN | claimed |
| EP-1680137-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | Intermune, Inc. (US) | 2006-07-19 | — | — | EP | claimed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| CN-115551917-B | Sequential targeting of cross-linked nanotherapeutics for the treatment of brain tumors | 加利福尼亚大学董事会 | 2025-06-13 | — | — | CN | disclosed |
| WO-2024123749-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USE THEREOF | INSTITUTE FOR SYSTEMS BIOLOGY (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20230076792-A1 | SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-09 | — | — | US | disclosed |
| EP-0371366-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1990-06-06 | — | — | EP | disclosed |
| WO-1990005736-A2 | NUCLEOSIDE ANALOGUES | MEDICAL RESEARCH COUNCIL (GB) | 1990-05-31 | — | — | WO | disclosed |
| EP-0350194-A2 | Control of electrokinetic potential by treatment with redox agents | BECKMAN INSTRUMENTS, INC. (US) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230076792-A1 | SEQUENTIAL TARGETING IN CROSSLINKING NANO-THERANOSTICS FOR TREATING BRAIN TUMORS | TIE1, CA12, CA13 | TK1 1878/4885LMNA 3488/4885TSHR 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.